Results 61 to 70 of about 54,330 (287)

Update on mantle cell lymphoma [PDF]

Blood, 2018
AbstractMantle cell lymphoma (MCL) is a rare subtype of non-Hodgkin lymphoma that is most commonly treated with combination chemo-immunotherapy at diagnosis because of the poor prognosis. More indolent presentations have been described including patients who can defer initial therapy without adverse impact on survival.
openaire   +2 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG

EJNMMI Research, 2020
Background In order to study the CXCR4 expression with [68Ga]pentixafor PET in different types of non-Hodgkin lymphoma, we performed a retrospective study to describe the [68Ga]pentixafor PET/CT imaging in a spectrum of lymphomas and to compare it with ...
Qingqing Pan, Yaping Luo, Yan Zhang, Long Chang, Ji Li, Xinxin Cao, Jian Li, Fang Li   +7 more
doaj   +1 more source

CD5– Mantle Cell Lymphoma [PDF]

American Journal of Clinical Pathology, 2002
Mantle cell lymphoma (MCL) typically expresses B-cell antigens and CD5 and overexpresses bcl-1 protein. However, unusual cases of bcl-1+ and CD5-MCL have been observed, posing a practical challenge for correct diagnosis and management. We identified 25 cases (48 samples) of bcl-1+ and CD5- lymphoma.
Zach, Liu, Henry Y, Dong, Wojciech, Gorczyca, Patricia, Tsang, Patti, Cohen, Christine F, Stephenson, Carol S, Berger, C Daniel, Wu, James, Weisberger   +8 more
openaire   +2 more sources

Synchronous pulmonary malignancies: atypical presentation of mantle cell lymphoma masking a lung malignancy

Rare Tumors, 2015
We present a case of a pleural space malignancy masked by an atypical presentation of mantle cell lymphoma. Our patient presented with a large pleural effusion and right sided pleural studding, initially attributed to a new diagnosis of mantle cell ...
Luke Masha, Andrey Zinchuk, Valia Boosalis   +2 more
doaj   +1 more source

Recurrent mantle cell lymphoma in the uterine cervix: a case report

Journal of Medical Case Reports, 2020
Background Mantle cell lymphoma is one of several subtypes of non-Hodgkin lymphoma. Cervical relapse of non-Hodgkin lymphoma is a very rare condition that has a variable and nonspecific presentation and may resemble other neoplastic or inflammatory ...
Giusi Santangelo, Innocenza Palaia, Giorgia Perniola, Anna Di Pinto, Angela Musella, Federica Tomao, Margherita Fischetti, Carolina Sassu, Mariagrazia Piccioni, Violante Di Donato, Pierluigi Benedetti Panici   +10 more
doaj   +1 more source

VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY. [PDF]

, 2023
Clémentine Sarkozy, Catherine Thiéblemont, Lucie Obéric, Philippe Moreau, Krimo Bouabdallah, Gandhi Damaj, T. Gastine, Vincent Ribrag, Olivier Casasnovas, Corinne Haïoun, Roch Houot, Fabrice Jardin, Éric Van Den Neste, Morgane Cheminant, Franck Morschhauser, M. Callana, Hervé Ghesquières, Rémy Gressin, Olivier Hermine, Steven Le Gouill   +19 more
openalex   +1 more source

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

Journal of Hematology & Oncology, 2018
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie, Michael Wang   +5 more
doaj   +1 more source

Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)-MCL0208 clinical trial. [PDF]

Hemasphere
Abstract Recent clinical trials have underscored the value of repeated minimal residual disease (MRD) measurements as a highly sensitive method for detecting subclinical disease and enabling dynamic risk stratification in hematologic malignancies. Despite its clinical potential, the complex and heterogeneous nature of MRD kinetics presents significant ...
Cordero F, Ferrero S, Pernice S, Genuardi E, Volpatto D, Sirovich R, Civita AM, Evangelista A, Ragaini S, Di Rocco A, Re A, Stefoni V, Cavallo F, Boccomini C, Balzarotti M, Zilioli VR, Gomes da Silva M, Arcaini L, Celli M, Zaccaria GM, Tortarolo D, Beccuti M, Hoster E, Pott C, Macintyre E, Hermine O, Dreyling M, Ladetto M.   +27 more
europepmc   +2 more sources